Rimonabant for treating tobacco dependence

Michael B. Steinberg, Jonathan Foulds

Research output: Contribution to journalReview articlepeer-review

14 Scopus citations

Abstract

Tobacco use continues to cause 5 million preventable deaths worldwide each year. Despite effective treatments being available, these are underutilized and cessation rates remain low. As tobacco use has complex physiological effects, there are multiple opportunities for novel pharmacological agents to play a role in a comprehensive treatment plan. The endocannabinoid system has been linked to the nicotine reward pathways in animal models. Rimonabant, a selective cannabinoid receptor (type 1) blocker, has been shown in some early clinical trials to have some positive effects in increasing abstinence rates of smokers attempting to stop. In addition, smokers who stop smoking with the assistance of rimonabant may gain less weight than those using placebo. However, the results from these few trials have not been entirely consistent and so its role as an aid to smoking cessation remains to be determined.

Original languageEnglish (US)
Pages (from-to)307-311
Number of pages5
JournalVascular Health and Risk Management
Volume3
Issue number3
StatePublished - Aug 13 2007

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Hematology
  • Public Health, Environmental and Occupational Health
  • Cardiology and Cardiovascular Medicine
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Rimonabant for treating tobacco dependence'. Together they form a unique fingerprint.

Cite this